Drug Profile
Research programme: anti-fungals - Elitra
Alternative Names: Anti-fungals research programme - ElitraLatest Information Update: 19 Apr 2007
Price :
$50
*
At a glance
- Originator Concordia University; Elitra Canada (CEASED); McGill University; Natural Sciences and Engineering Research Council of Canada; University of Toronto
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 19 Apr 2007 Discontinued - Preclinical for Mycoses in Canada (unspecified route)
- 02 Jul 2002 This programme is still in active development
- 22 Dec 2000 Mycota Biosciences has been acquired by Elitra Pharmaceuticals and renamed Elitra Canada